

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
05 October 2023 (05.10.2023)



(10) International Publication Number
WO 2023/187677 A1

(51) International Patent Classification:

A61P 25/00 (2006.01) C07D 221/20 (2006.01)
A61P 25/28 (2006.01) C07D 487/04 (2006.01)
C07D 207/22 (2006.01) A61K 31/4468 (2006.01)
C07D 209/54 (2006.01) A61K 31/403 (2006.01)
C07D 211/58 (2006.01) A61K 31/40 (2006.01)

(21) International Application Number:

PCT/IB2023/053132

(22) International Filing Date:

29 March 2023 (29.03.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/325,452 30 March 2022 (30.03.2022) US

(71) Applicant: **TAKEDA PHARMACEUTICAL COMPANY LIMITED** [JP/JP]; 1-1, Doshomachii 4-chome, Chuo-ku, Osaka-shi, Osaka, 541-0045 (JP).

(72) Inventors: **HOPKINS, Maria**; c/o Takeda Development Center Americas, Inc., 9625 Towne Centre Drive, San Diego, California 92121 (US). **KIRYANOV, Andre**; c/o Takeda Development Center Americas, Inc., 9625 Towne Centre Drive, San Diego, California 92121 (US). **SCHLEICHER, Kristin**; c/o Takeda Development Center Americas, Inc., 9625 Towne Centre Drive, San Diego, California 92121 (US). **TANG, Mingnam**; c/o Takeda Development Center Americas, Inc., 9625 Towne Centre Drive, San Diego, California 92121 (US). **ZHOU, Feng**; c/o Takeda Development Center Americas, Inc., 9625 Towne Centre Drive, San Diego, California 92121 (US). **CHERUVALATH, Zacharia**; c/o Takeda Development Center Americas, Inc., 9625 Towne Centre Drive, San Diego, California 92121 (US). **OLSEN, Scott**; c/o Takeda Development Center Americas, Inc., 9625 Towne Centre Drive, San Diego, California 92121 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,


HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: N-(PYRROLIDIN-3-YL OR PIPERIDIN-4-YL)ACETAMIDE DERIVATIVES



(1)

(57) Abstract: Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein L⁶, n, R², R³, R⁴, R⁵, R⁷, R⁸, R⁹, R¹⁰, R¹¹, R¹², R¹³, R¹⁴, R¹⁵ and X¹ are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating diseases, disorders, and conditions associated with SSTR4.

WO 2023/187677 A1